EL PASO, TX--(Marketwired - September 27, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has manufactured and shipped initial design sample pain relieving topical patches for distribution to select VA hospital patients, military personnel, doctors, and professional sports figures. These patent-pending, opioid- and narcotic-free all-natural-ingredient topical pain relief patches consist of a proprietary mechanism for extended delivery of their cannabis-based medical CBD pain relieving compound, which is legal in all 50 states.
William A. Hartman, President and CEO of Premier Biomedical, said, “These initial production samples will provide us with valuable information and exposure for what we believe is a vastly superior-performing product, leading to customer demand that will facilitate our marketing plans going forward. If results are as positive as our in-house trials have been, we should be in a position to begin ramping up production almost immediately. PBPMS is planning a complete line of pain management products in addition to these topical skin patches, to include roll-ons, creams, sprays, lip balms, and capsules. Initially, we plan that these products will be available for sale in all 50 states via the Internet and possibly through other retail channels, and/or potential partnered pharmaceutical relationships, beginning as early as the first quarter of 2017.”
Ron La Borde, Managing Director of Premier Biomedical Pain Management Solutions, indicated, “Our particular product design is far superior to our competitors in that our extended delivery pain relief topical patch can deliver relief for up to four days compared to less than a day for many of the leading competitive patches. Our proprietary combination of natural ingredients will offer more effective pain relief while our patent-pending patch design will provide much needed long term pain relief though continuous delivery of our pain relieving product. Our laser-controlled manufacturing process insures uniform quality of our products and assured performance for our customers.”
About Advanced Technologies Solutions
Advanced Technologies Solutions is a San Diego, California based company and a leader in transdermal patch technology for the administration of natural ingredient products to relieve localized and general pain, which has been a focal point for the owner and founder of the company. With 35 plus years of experience in science, engineering and medical diagnostics, ATS brings together aspects of design, natural product formulation, production and automation in the manufacture of pain management devices.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Visit Us on Investors Hangout http://investorshangout.com/Premier-Biomedical-Inc-BIEI-88326/
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
http://www.premierbiomedical.com/
